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Summary and Concluding Remarks
In yivo quantil ication of B-adrenoccptors in the brain, hcart and lung could be very valuablc
for the investigation of thesc rcceptors in ncuropathologies, myocardial and pulmonary
diseascs, irnd for monitoring the elfects of treatment. The airn of this thesis was the
development of a method to image p-adrenoceptors in thc human brain and hcart with PET
and the validation of a tracer kinetic model to ir yi lo quantify receptor dcnsities.
Cereb ral p-adrenoceptor imaging
For quantif ication of B-aclrenoceptors in the brain, the radioligand S-l '-[ ' 'F]tluorocarazolol
scemed to be an cxccllent candiclate. It is a fluorinated analog of thc potent, non-subtype
selcctive p-adrenoceptor antagonist carazolol, and exhibits specific in vivrt bincling to ccrebral
(14), rnyocardial and puluronary ( 1 5) p-adlcnoceptors in hurnarrs. ln ordcr to assess (ccrebral)
p,adrenoceptor clensitics (8,,,,,.) quantitativcly with PET and S- l '-11*F]tluorocarazolol, a tracer
kinetic rnodel 15) is requirecl. Chapter I l clemonstrated that S-l '-[ '*Flf luorocarazolol mccrts all
the requircments for a traccr-kinetic nrodel such as proposed by Delfbrge ct a/ (5). Thesc
include lor.v metabolite levcls in brain, saturabil ity and revcrsitri l i ty of thc receptor binding in
rats.
S- I '-[rEF]fluorocarazolol levcls in brain were relatively low. This aflccts thc count
statistics and theretbre thc quality of the PET irnages. In chapter III the possibil i ty to
cnhancc fhe cerebral uptake of S-l '-[ lsF]tluorocarazolol, without aftccting its regional
distribution. was dcmonstrated by modulating the transmembranc protein P-glycoprotein u ith
Cyclosporin A in the blood-brain ban'ier (BBB) of rats. Coadministration of P-gp rnodulators
rnay thereforc improve the quality of PET images of p-adrenoceptors in thc brain. However,
the ntodulator Cyclosporin A cannot be uscd in healthy voluntcers, because of its toxicity
(12). More potent and highly specific P-gp modulators, such as t-Y335979 (2) and the non-
imrnunosuppressive cyclosporin D analog SDZ PSC 831 (10) have already been rcporled.
Because of thcir potcncy ancl specificity, such conrpounds may be suitablc fbr application in
hurnan PET studies.
Since the application of a tracer kinct ic model requires mult iple inject ions and the addit ion
of carr ier to thc radiol igand, a toxicological stucly of S-l ' - ;rEFlf luorocarazolol (see chapter
I! ' )  was perfbrmecl. Unfortunately. the introduction of f luotinc in the B-blocker carazolol
t ' ielded a compound lvi t l .r  strong r lutagenic potency as r.ncasurecl by the Amcs test. Thereforc.
carr icr-added studies with S-1'-1'*F]f luorocaruzolol in hurnans arc precluded. Fufiher rcscarch
to elucidatc i f  this radiol igand is a r isk to humans should addrcss the genotoxic and/or
carcinogenic potcncy of S-f luorocarazolol in rnammalian ccl ls and in ( long tcrm) rn l i lo
expeflmcnts.
Toxicity test ing of ncwly developed radioactive pharmaccuticals dif fers nrarkcdly f iom
nrost rnedicinal products, becausc rnostly small ,  not pharmacological ly act ive cluanti t ies arc
involvcd and repeated studics are exceptional. Therefore, rcpcatcd dose toxicity studies of
novcl ladiopharrnaceuticals rnay be omitted, but single dose toxicit l 'and genotoxicit t 'studies
should be irrcluclcd, bcfbre the test drugs ale irdnrinistcrcd to hurnans. This approach r.vas
recently dcmonstrated fbr thc radiol igand P-C'lT (7). To propcrly assess the possible
gcnotoxicity of a ncwly developed racl iol igand. a battcry of tests is recommcnded by the
International ( 'ont 'erence on Harnronization of Tcchnical Requircrncnts fbr Registrat ion of
Pharrnaceuticals 1or Hunrau Llse ( lCH gi,r idel ines 52B). This includes a tcst fbl sene lnutat ion
in bactcria, an irr t ' i tnt tcst wit lr  cytogcnic cvalrrat ion of chromosornal damagc (c.g. human
lymphocycs) and an irr ui lo tcst for chrornosomal darnage (rodent hcmatopoiet ic cel ls).  This
battcry of tests shrruld bc pcrfblrnecl not only bcfbre carr ier-addcd doses of the nclr 'compound
are adnrinistcrcd (rnult i- injcct ion protocols for rcccptor density,asscssurent), but also bcfbre
PET studics at the non-carr icr added level arc init iated, sincc gcnotoxicity is not a l incar but a
stochastic process. A rcal dose-risk assessrncnt lbr humans can ncver be made with the data
f iom the gcnotoxicity tests.
To f ind alternativcs tbr S-l ' -1r*Flt luolocarazolol.  f lvc ncw raci iotraccrs with high aff ini t1,
lbr the B-adlcnoccptor and nrodcratcly high l ipophil ici ty u,ere synthcsizetl  (chapter V).
Evaluation of these radiotracers for i t t  viyo imaging of B-adrcnoceptors in thc blain. together
- t r i - - .
rvith [ '- ' [] iodocylnopindolol (standard l igand tbr autoradiography), revealed that cerebral
uptakc of these ligancls was either too low ol not rclatcd to p-adrenoccptors. even though
sorre radioligands did display strrccil ic binding in lung and heart. Although a high Kp and
(rnodcratcly) high l ipophil icity are oflen uscd as prerequisitcs fbr the suitabil ity of a
compound fbr irr l i l ,o irnaging of cercbral receplors, thcsc criteria, combincd with available
phannacokinctic ntbrmation. provccl rrot sufficicnt o select a suitablc p-adrenergic l igand for
ccrcbral [3-adlenoceptor imaging. Possible reasons include transport by P-glycoprotein,
rrrctabolisrr, protein binding ancl unccrtainties in thc K1;1 values, as dctcrminerl in in vitro
assays.
Anothcr canditlatc fbr celebral B-adrcnoceptor irnaging u,ith favorablc attinity and
lipophil icity, (S)-[ 'nF]f ' luorocthylcarazolol c uld be successlirl ly synthesizecl fbr animal
stLrdics (chaptcr VI). Evaluation in rats demorrstrated its potency and spccific binding to
cerebral B-adrcnoccptors i / /  r , i r?, anrl  i r t  t ' iuo in rats. This novel radiol igand is theretbre of '
potcntial usc fbr B-adrcnoccptor inraging in thc brain with PET. Whcther (S)-
I l sF l f luoroc thy lcarazo lo l  i s  gcnotox ic  l i kc  (S) - [ rsF ] t luorocarazo lo l .  remains  to  be  exanr incd .
The n.rutagcnic properl ics of carazolol analogucs alc harcl to predict since (S)-f luorocarazolol
shorved rnutagcnic activi ty in thc Amcs test whelcas (S)-carazolol did not (6).
l f  (S)-[ ' tF' ] f luoloethvlcarazolol has proven to be non-toxic, pi lot studies with this l igand
can bc perfbrmcd in voluntecrs. To pt ' t ' rduce suff icicnt anrounts of (S)-
IrEFlf luorocthylcarazolol,  the synthctic loute via f luolo-ethvlal ion of (S)-clesisoplopyl u' i l l  be
investigated. To r lcasurc Bn,^* o tracer kinetic mcldcl (sec chaptcr Vl l)  rnight be applicd.
Ho'uvcver. tbr recclt tor quanti f icat ion in the brain binding lrotentials (BP) nray bc sufl lcient.
which can be estimatcd using a rcgion with rnainly non-specif ic bindirrg as ref 'ercnce t issue.
For p-adrenoceptors this is sl ightly ci i t t icult  bccausc thesc reccptols are widely distr ibuted
throughout the brain. White matter of thc corpus cal losum rnay bc used as a rcference region,
since the p-adrenoceptor densitf  in this rcgion is known to bc very low.
Subscquently, 1S1-[rEt- l f luoroethylcarazolol can be applicd to quanti ly B-adrcnoccptors in
the brains of patients suffering f iorn rnood disordcrs (e.g. depression), clegcnerative diseases
(e.g. Alzhcimer's cl isease). and also in patients suf ' f l r ing f iorn rr.rult iplc sclcrosis (MS). This
last group of patients displays a lack of astt 'ocyt ic B:-adrenoceptors in Trrrs/ /r , , / /e' l l  t issr. lc.
rvhich may be involr. ,ed in thc induction or perl)ctuation of autoirnnrunc rei ict iorts (3). Mult iple
in t , i t ,o mcasuremcnts with PET and 15.y-[ ' 'F]f luorocthylcarazolol can probably be used to
rnonitor discase progrcssion and rrray al lou, dif- lerential diagnosis of MS ancl other
neurodegcnerative discases.
Irurthcnnorc, PET and 1S1-[rsF]f lLr.rroetlr ] , lcalazrr lol nra,v prove to be a'"alLrable tcchniquc
to assess reccptor occupancy of central ly act ing [3-blockcrs. This rnight rcveal i f  thc
mcchanisrns of act ior.r of B-blockers in a variety of brain pathologics not ini t ial ly assctciatccl
w i th  B-adrenoccptors ,  inc lud ing  migra ine  (16)  and (1 .8 )  suddcn card iac  dca th  (9 ) .  a rc  le la tcd
to p-adrerroccptor binding, scrotonin reccptor binding, non-spccif ic nrembrane stahi l izing
prol.rcrt ies or pcripheral ly mediatcd activi ty (17). Morcorer, (S)-[r*F]f luoroethylcarazolol-
PET could elucidate the rclat ionship betwccn p-adrenoceptor occupancy and side cffects,
such as hal lucination, depression, insolnnia. fat iguc. dizziness. impairccl shofi- ternr merlory
and a le f tncss  ( rcv iewcd in  (8 ,1  l ) ) .
Myocardial and pulmonary B-adrenoceptor imaging
Chapter VII deals with the imaging of p-adrenoceptors in hutnan heart.  Thc radiol iganci
["C]CGp 12388 produced excel lcnt irnages of B-adrenoccptors in thc heart,  lung and spleen
of healthy voluntecrs. Bccausc of i ts favorable phannacokinetic (e.g. low rnctabolisrn) ancl
pharmacot lynar r ic  (e .g .  spec i l i c  b ind ing  w i th  h igh  assoc ia t ion  ra tcs )  p roper t i cs .  {S t - [ r 'C lCC;e
12388 appears sr"r i table tbr quanti tat ivc PET studics using a rnult i- inject ion protocol.
Traccr-kinetic modeling allowed the estimation of all ntodel parameters of (S)-["C]CGP
l238ii (chapter VIII). 8,,,,,. and K11 w€r€ rcliably calculated in the rvhole left ventricle and
regional dit lcrences could be plotted in a pararnetric polar map (120 differcnt segments). We
conclude that (S)-[r 'C1CCe 12388 in combination with a tracer-kinetic model is useful for
calcrrlating rcgional B,,,,,. values in hunran lefl ventricle in vivo.
Data fiom various injection protocols appeared to allow calculation of reliable B,no^ valucs.
The flt procedure appearecl to bc equally scnsitive to changes in thc value of thc parameters.
The ideal protocol horvever, should bc most sensitive to tl ie paranreter B,,,,,,, while the
scnsitivity to thc other paralneters i lcss essential. Simulation of different injection protocols
(various injected masses and injcction intervals). based on the acquircd data, should reveal thc
optinral injection protocol and rvhethcr thlee injcctions are cssential or not. Obviously. a
protocol with a rninimal number of injections is prefcrred becausc it is morc convenient in a
clinical sctting.
The protocol may be turther sinrpli l icd by using tlre bloodpool (endocardium) as input
function in stcad of the arterial sarnples, which reduces thc inconvenienccs for the patient.
(S)- [ r rC]CGP 12388,  howu,cr  shows substant ia I  b inding to rcc l  b looc]  ce l ls  (chapter  VI I ) .
Thelefbre, using the whole blood as input f iurction to accurately rlodcl the kinetics of the
ligand, is probably only fbasible when the bloodpool data is (dynamically) correctcd lor red
blood cel l  b inding.
When the optimal plotocol is tbund, the 8,,,.* can be assessed in patients suffering l iom
HCIM, DCM or other myocardial deficicncies and compared to those found in healthy
volunteers. Since traccr kinetic modcling in principle allorvs the identif ication of all model
pararncters vr'hilc requil ing only standard u priori assunrptions, it could scrl 'c as a gold
standard to validatc simplif icd procedurcs including graphical models, which are based on
rnany additional hypothcses and oftcn allow only the idcntif ication of conrpositcs of
parameters (c.g. B,,,,,,/ Kp, r 'ather than B,,,,,").
f ' ]-Adrenoccptors were also visualizcd with (S)-[ ' C]CGP 12388 in thc lungs of healthy
volunteers. This technique however is probably not suitable to detect diffcrences in p-
adrerrcrccptors in  COPD, as was a l ready c lemonstrated wi th (St- [ r 'C]CCR l2 l ]7  in  asthmat ic
sub.jects vcrsus age-matched healthy controls (13). Intravctously achninistered radioligand
mainly binds to alveolar rcceptors (> 900,6). and much less (< 10%) to rcccptors on smooth
muscle cclls in the uppcr airways (see also (15)). which are involved in the regulation of
airway calibcr and thus contributes to the pathophysiology of COPD. Thercfore, it would be
lal rnore intcresting to image exclusively B-adrcnoceptors in the upper airways. This rnight be
possib le by adnr in is ter ing (S)- [  C]CGP 12388 r ' ia  inhalat ion.  (S)- [ '  C]CGP 12388 inhalat ion
rnay also be usccl to assess B-adrenoccptor occupancy of B-mimetics and to deterrnine the
pat tern ofdeposi t ion ofvar ious inhalers and ncbul izers.
